Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Systemic Lupus Erythematosus: Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Systemic Lupus...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Systemic Lupus Erythematosus

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Systemic Sclerosis (Scleroderma): Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Systemic Sclerosis...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Systemic Sclerosis (Scleroderma)

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Anti-Neutrophil Cytoplasmic...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis)

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Sicca Syndrome (Sjogren): Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Sicca Syndrome...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Sicca Syndrome (Sjogren)

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Dermatomyositis: Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Dermatomyositis. According...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Dermatomyositis

Data Insights

CD19 Targeted CAR-T Therapy by Chongqing Precision Biotech for Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Likelihood of Approval

CD19 Targeted CAR-T Therapy is under clinical development by Chongqing Precision Biotech and currently in Phase I for Granulomatosis with...

Likelihood of Approval and Phase Transition Success Rate Model - CD19 Targeted CAR-T Therapy in Granulomatosis with Polyangiitis (Wegener's Granulomatosis)